Skip to content

Research on the Mechanism of Time Interference Stimulation in Regulating Neuroimmune and Cognitive Functions in the Hippocampus of Schizophrenia

Research on the Mechanism of Time Interference Stimulation in Regulating Neuroimmune and Cognitive Functions in the Hippocampus of Schizophrenia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500104226
Enrollment
Unknown
Registered
2025-06-12
Start date
2025-06-16
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Really Exciting Group:A full set of MCCB tests, electroencephalogram (EEG) tests, niacin tests, and head magnetic resonance imaging (MRI) examinations were conducted. Blood samples were collected. The
Pseudo-stimulation group:The process was the same as that of the true stimulation group. During the intervention, the TI treatment instrument was set to pseudo-stimulation and given for 10 seconds Sto

Sponsors

Nantong Fourth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 45 Years

Inclusion criteria

Inclusion criteria: (1) Meet the diagnostic criteria of schizophrenia in DSM-V; (2) Agree to accept subjects with first-episode schizophrenia : (1) Meet the diagnostic criteria of schizophrenia in DSM-V; (2) Agree to receive neuroregulation therapy and sign the informed consent form; (3) Age range: Between 14 and 45 years old; (4) IQ > 69; (5) The first onset and no systematic antipsychotic drug treatment (=60 points; (7) In the MCCB score, the visuospatial factor score is <=6 points and T is <=26 points.

Exclusion criteria

Exclusion criteria: (1) Subjects with obvious tendencies of impulsive or negative and other dangerous behaviors; (2) Have other axial I mental disorders other than schizophrenia; (3) There has been drug or alcohol dependence within the past three months, or currently taking anti-inflammatory drugs or suffering from chronic inflammatory diseases (such as rheumatoid arthritis or inflammatory bowel disease); (4) Sensorimotor disorders (e.g., hearing impairment, blindness), neurological diseases (brain injury, epilepsy), or other physical diseases that can explain psychotic symptoms or high-risk symptoms; (5) Those with claustrophobia who are unable to undergo magnetic resonance scans; (6) Those with metal implants in their bodies; (7) Inability to provide informed consent or understanding research.

Design outcomes

Primary

MeasureTime frame
MATRICS Consensus Cognition Suite Test;Positive and Negative Syndrome Scale;Hamilton Depression Scale;Hamilton Anxiety Scale;Clinical Global Impression;Global Assessment of Function;Electroencephalogram detection;

Secondary

MeasureTime frame
Niacin test;Peripheral blood immune factors;

Countries

China

Contacts

Public ContactChen Xing

Nantong Fourth People's Hospital

Cx109003143@qq.com+86 151 5243 1456

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026